Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nippon Chemiphar Successfully Reverses Decline

Annual Results See Company Make Up Shortfall From Earlier In The Year

Executive Summary

Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022. 

You may also be interested in...



Nichi-Iko Resumes Production After Suspension

Nichi Iko says it has restarted production at its Namerikawa manufacturing plant after the Japanese firm was forced to suspend operations due to alleged GMP violations.

Nippon Chemiphar Is Managing To Slow Its Decline

Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast. 

US FDA Focuses On Harmonization With The Launch Of Generic Drug Cluster

To improve common standards for global development for generics and access to generics, FDA has launched the Generic Drug Cluster through the Global Generic Drug Affairs team established by the FDA’s Office of Generic Drugs. The agency has listed objectives through which it aims to increase scientific alignment among leading generic drug regulatory agencies. 

Topics

Related Companies

UsernamePublicRestriction

Register

GB150986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel